Cargando…

Effect of Treatment with Colchicine after Acute Coronary Syndrome on Major Cardiovascular Events: A Systematic Review and Meta-Analysis of Clinical Trials

AIM: Colchicine as an anti-inflammatory drug might be effective in the treatment of atherosclerosis, an inflammatory-based condition. The aim of this systematic review and meta-analysis was to evaluate the impact of colchicine on acute coronary syndrome (ACS). METHODS: We searched SCOPUS, PubMed, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Razavi, Erfan, Ramezani, Akam, Kazemi, Asma, Attar, Armin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020977/ https://www.ncbi.nlm.nih.gov/pubmed/35495414 http://dx.doi.org/10.1155/2022/8317011

Ejemplares similares

Major cardiovascular events after bone marrow mononuclear cell transplantation following acute myocardial infarction: an updated post-BAMI meta-analysis of randomized controlled trials
por: Attar, Armin, et al.
Publicado: (2022)

Colchicine in the Management of Acute Coronary Syndrome: A Meta-analysis
por: Nogic, Jason, et al.
Publicado: (2023)

Correction to: Colchicine in the Management of Acute Coronary Syndrome: A Meta-analysis
por: Nogic, Jason, et al.
Publicado: (2023)

Correction to: Colchicine in the Management of Acute Coronary Syndrome: A Meta-analysis
por: Nogic, Jason, et al.
Publicado: (2023)

Is There a Role for Colchicine in Acute Coronary Syndromes?
por: Nidorf, Stefan M, et al.
Publicado: (2015)

Early long-term low-dosage colchicine and major adverse cardiovascular events in patients with acute myocardial infarction: a systematic review and meta-analysis
por: Zhou, Yifang, et al.
Publicado: (2023)

Cost-Effectiveness of Colchicine for Recurrent Cardiovascular Events
por: Boczar, Kevin E., et al.
Publicado: (2023)

Colchicine poisoning treated with hemoperfusion and hemodialysis: A case report
por: Ramezani, Maral, et al.
Publicado: (2022)

Risk factors for major adverse cardiovascular events after the first acute coronary syndrome
por: Okkonen, Marjo, et al.
Publicado: (2021)

Comparing the effect of bone marrow mono-nuclear cells with mesenchymal stem cells after acute myocardial infarction on improvement of left ventricular function: a meta-analysis of clinical trials
por: Hosseinpour, Alireza, et al.
Publicado: (2022)

Is There a Role for Colchicine in Acute Coronary Syndromes? A Literature Review
por: Malik, Jahanzeb, et al.
Publicado: (2020)

Is Colchicine a New Game-Changer in Patients With Acute Coronary Syndrome?
por: Nawabi, Abdul Q, et al.
Publicado: (2022)

Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial
por: Akrami, Mehdi, et al.
Publicado: (2021)

The prognostic effect of ST-elevation in lead aVR on coronary artery disease, and outcome in acute coronary syndrome patients: a systematic review and meta-analysis
por: Kazemi, Erfan, et al.
Publicado: (2022)

Mesenchymal stem cell transplantation after acute myocardial infarction: a meta-analysis of clinical trials
por: Attar, Armin, et al.
Publicado: (2021)

Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome
por: Martínez, Gonzalo J, et al.
Publicado: (2015)

Value of Manchester Acute Coronary Syndromes Decision Rule in the Detection of Acute Coronary Syndrome; a Systematic Review and Meta-Analysis
por: Ramezani, Fatemeh, et al.
Publicado: (2018)

Low-Dose Colchicine in Coronary Artery Disease　― Systematic Review and Meta-Analysis ―
por: Abrantes, Ana Mafalda, et al.
Publicado: (2021)

Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention
por: Vaidya, Kaivan, et al.
Publicado: (2020)

Development and Validation of a Nomogram of In-hospital Major Adverse Cardiovascular and Cerebrovascular Events in Patients With Acute Coronary Syndrome
por: Bo, Xiangwei, et al.
Publicado: (2021)

A prognostic nomogram for long-term major adverse cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention
por: Kong, Shuting, et al.
Publicado: (2021)

Modulating inflammation to reduce atherosclerotic cardiovascular events: should colchicine be part of the therapeutic regimen?
por: Jialal, Ishwarlal, et al.
Publicado: (2021)

Efficacy and Safety of Colchicine in Prevention of Secondary Cardiovascular Outcomes Among Patients With Coronary Vessel Disease: A Meta-Analysis
por: Sattar, Lubna, et al.
Publicado: (2022)

Effects of thyroid hormones on major cardiovascular risk in acute coronary syndromes
por: Bayrak, A, et al.
Publicado: (2011)

New genetic variants associated with major adverse cardiovascular events in patients with acute coronary syndromes and treated with clopidogrel and aspirin
por: Liu, Xiaomin, et al.
Publicado: (2021)

Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
por: Bouabdallaoui, Nadia, et al.
Publicado: (2020)

Glycaemic variability and risk of adverse cardiovascular events in acute coronary syndrome
por: Zhang, Lei, et al.
Publicado: (2022)

Colchicine in Patients With Coronary Artery Disease: A Systematic Review and Meta‐Analysis of Randomized Trials
por: Kofler, Thomas, et al.
Publicado: (2021)

A Meta-Analysis Evaluating the Colchicine Therapy in Patients With Coronary Artery Disease
por: Grajek, Stefan, et al.
Publicado: (2021)

Meta-analysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome
por: Lutschinger, Leon L., et al.
Publicado: (2019)

Is the variation in monocyte to high-density lipoprotein cholesterol ratio a predictor of major cardiovascular events after acute coronary syndrome?
por: Figueiredo, E.T., et al.
Publicado: (2023)

Colchicine for Coronary Artery Disease: A Review
por: Chen, Tao, et al.
Publicado: (2022)

Correlation between monocyte to high-density lipoprotein ratio and major adverse cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention
por: Yu, Rong, et al.
Publicado: (2021)

Colchicine — From rheumatology to the new kid on the block: Coronary syndromes and COVID-19
por: Surma, Stanisław, et al.
Publicado: (2023)

Colchicine efficacy and safety for the treatment of cardiovascular diseases
por: Andreis, Alessandro, et al.
Publicado: (2021)

Risk of coronary artery disease in patients with gout on treatment with Colchicine: A systematic review and meta-analysis
por: Siddiqui, Muhammad U., et al.
Publicado: (2023)

Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
por: Samuel, Michelle, et al.
Publicado: (2020)

An Updated Meta-Analysis of RCTs of Colchicine for Stroke Prevention in Patients with Coronary Artery Disease
por: Katsanos, Aristeidis H., et al.
Publicado: (2021)

The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention
por: Giantini, Astuti, et al.
Publicado: (2023)

Serum tryptase detected during acute coronary syndrome is significantly related to the development of major adverse cardiovascular events after 2 years
por: Pastorello, Elide Anna, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_agkfhf9ogmjlaklnnb6cjse2uf